For me, this hits close to home. We’ve seen what happened with lomustine and the impact on brain tumor patients when a life-saving therapy becomes inaccessible. These aren’t abstract policy issues — they have real consequences for people. @eddiecliff.bsky.social @mskcancercenter.bsky.social

Just out at JNCI, we review 20 years of RCTs in myeloma for lessons in drug development. Surprisingly, head-to-head trials were as likely to be successful as add-on trials. academic.oup.com/jnci/advance... #mmsm #myeloma

Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm. Thanks David Russler-Germain + collabs aacrjournals.org/clincancerre...

The US Food and Drug Administration accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines. ja.ma/3Kz6WnV

RW pola outcomes by Hans COO @eddiecliff.bsky.social - 740 pts, 59% R/R - R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC - 1L: no diff in outcomes Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm aacrjournals.org/clincancerre...

The urgency is real—but the “Most Favored Nation” drug pricing policy is unlikely to deliver lasting reform. In @jama.com, @eddiecliff.bsky.social and I propose accelerating and strengthening Medicare drug price negotiation to align prices with value. 🔗 jamanetwork.com/journals/jam...

Viewpoint: The reintroduction of the most favored nation pricing policy aims to curb high US drug prices but faces legal and operational challenges. ja.ma/4lXJcYs

Just out @jama.com, led by Ian Liu we review 10 years of nononcology accelerated approvals 12/50 vaccines 10 nonmalignant haem 11 neurology 5 nonvaccine ID >60% conversions to regular approval based on surrogate endpoints jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social

The US FDA accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines. https://ja.ma/4lRpuge

Currently at #EHA2025: @broeckelmann.bsky.social presenting our recent @thelancethaem.bsky.social commission on adverse events, starting with our paper (with @biostatgirl.bsky.social) on advancing the measurement & dissemination of AE data HT @eddiecliff.bsky.social #EHA25

🔍Presenting at #ASCO25 as a #poster and now LIVE on our website Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study Read the whole paper here: www.thelancet.com/journals/ecl... #TheLancet #Oncology #OncologyResearch #MedSky

Announcing the 1st paper of ‪@thelancethaem.bsky.social‬ Commission on Adverse Events, with Drs. @biostatgirl.bsky.social‬ & Thanarajasingam. We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination. buff.ly/SchRHhq Thread ⬇️🧵

What steps can trialists, regulators, journals, editors, reviewers, sponsors & academics take to improve toxicity reporting & identification? 👇 check out this figure from our @thelancethaem.bsky.social adverse event commission www.thelancet.com/journals/lan... @broeckelmann.bsky.social

For the third (open access) paper, I was humbled to coordinate an international author panel to comprehensively summarize challenges, lessons learned and outline future strategies for tolerability assessment with novel, targeted therapeutic approaches: doi.org/10.1016/S235...

The latest in a trio of meta-analyses by Tobias, David & Kai just out at Molecular Therapy, on non-relapse mortality after bispecific antibodies in lymphoma & myeloma. >70% of non-relapse deaths are due to infection. Need to prioritise measurement, reporting, prophylaxis, early intervention.

Just out @jama.com Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas jamanetwork.com/journals/jam... @portalresearch.org

Delighted Piers Blombery joined us to discuss CAR transgenic T-cell lymphoproliferative neoplasms & all things post-CAR-T malignancies on Blood Cancer Talks, with a side helping of molecular haematology. We discuss Piers' recent NEJM paper plus recent MSKCC case w transgene integration into TP53.

A real honour to have Dr Hagop Kantarjian, M.D. on the podcast to talk all things CML, including the recent ASCEMBL trial - a really enjoyable hour packed full of wisdom! podcasts.apple.com/us/podcast/b... Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml

Helpful review on ctDNA in aggressive B-cell lymphomas just out in @jama.com oncology jamanetwork.com/journals/jam... #lymsm #lymphoma

Enticing data for axi-cel in high risk upfront DLBCL in ZUMA-12 3 year followup @BloodJournal 75% 3-year progression free survival ashpublications.org/blood/articl... Randomised ZUMA-23 data eagerly awaited #lymsm #lymphoma

Disappointing outcomes for CAR T cells in 31 patients with relapsed/refractory Burkitt lymphoma Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control ashpublications.org/blood/articl... #lymsm #lymphoma

SYMPATICO trial - RCT of venetoclax + ibrutinib vs ibr+placebo in R/R mantle cell lymphoma just out in Lancet Oncology www.sciencedirect.com/science/arti... #lymphoma #lymsm

Updated European guideline on Burkitt lymphoma just out in Lancet Haem - www.thelancet.com/journals/lan... #lymsm #lymphoma #burkitt

New piece led by Anushka Bhaskar @portalresearch.org in STAT First Opinion on protecting public health agencies from damaging political interference -- even the threat of which can greatly affect people's behavior: www.statnews.com/2025/01/31/p...

The new administration's FDA -- threat or opportunity for public health? A piece in Health Affairs Forefront with @akesselheim.bsky.social www.healthaffairs.org/content/fore...

Check out important new Viewpoint from @portalresearch.org collaborators @eddiecliff.bsky.social and Kerstin Vokinger on regulatory oversight of AI-enabled medical devices in JAMA Neurology: jamanetwork.com/journals/jam...

Financial toxicity in cancer meds: @portalresearch.org's collaborator @eddiecliff.bsky.social and others review the potential financial implications of receiving vorasidenib for glioma and how different countries manage the high cost: academic.oup.com/nop/advance-...

Also the importance of actually assessing clinical endpoints in confirmatory studies (pubmed.ncbi.nlm.nih.gov/38583175/) ... and completing them in a timely fashion (pubmed.ncbi.nlm.nih.gov/39373384/) - studies from @eddiecliff.bsky.social Ian Liu Joseph Daval at @portalresearch.org

Relevant to accelerated approval, new DCE from former @portalresearch.org fellow Huseyin Naci et al examined patient views on survival benefit for cancer drugs: "individuals expressed strong preferences for certainty that a cancer drug would offer survival benefit" www.thelancet.com/journals/lan...

Just out at JAMA Oncology, led by Parsa Erfani We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity jamanetwork.com/journals/jam...

Just out in Nature Reviews Clinical Oncology: we explain why ibrutinib's mantle cell lymphoma indication should *not* have been withdrawn, dissect SHINE & TRIANGLE trial results & suggest what the FDA could have done instead rdcu.be/dmGJu #healthpolicy #lymsm #mmsm